Physician profile
Boyd Andrews
NPI 1720333792
$1,657.38
in general payments reported to CMS, 2019-2025
28 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $380 · 2021: $282 · 2022: $403 · 2023: $78.94 · 2024: $50.19 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $192.95 | 2019-2021 | |
| Grt US Holding, INC. | $163.87 | 2021-2022 | |
| Stryker Corporation | $159.46 | 2021-2024 | Ortholoc 2 Lapifuse, Easyfuse, 7 X 23mm Citrelock Implant |
| Organogenesis INC. | $152.10 | 2019-2022 | |
| Djo, LLC | $142.60 | 2019-2021 | |
| Treace Medical Concepts, INC. | $131.67 | 2022 | |
| Rikco International, LLC | $110.35 | 2019-2020 | |
| Abbvie INC. | $82.00 | 2021-2022 | |
| Allergan, INC. | $81.15 | 2020 | |
| Integra Lifesciences Corporation | $68.81 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Melinta Therapeutics, LLC | $58.07 | 2019-2021 | |
| Smith+Nephew, INC. | $47.25 | 2021 | |
| Depuy Synthes Sales INC. | $35.72 | 2024-2025 | Motoband |
| Kci USA, INC. | $30.21 | 2020 | |
| Medtronic, INC. | $19.11 | 2025 | Inceptiv |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $19.06 | 2021 | |
| Medtronic Vascular, INC. | $18.29 | 2020 | |
| Zimmer Biomet Holdings, INC. | $18.01 | 2019 | |
| Glenmark Therapeutics INC. | $16.00 | 2019 | |
| Pfizer INC. | $15.80 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.36 | 2021 | |
| Nabriva Therapeutics, Plc | $14.15 | 2021 | |
| Celularity INC. | $14.00 | 2019 | |
| Hikma Pharmaceuticals USA | $12.05 | 2019 | |
| Tactile Systems Technology INC | $12.00 | 2019 | |
| Assertio Therapeutics, INC. | $11.91 | 2019 | |
| Merck Sharp & Dohme LLC | $11.67 | 2019 | |
| Orthofix Medical, INC. | $4.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyd Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.